Utpal Koppikar Acquires Shares in C4 Therapeutics

Utpal Koppikar recently made a notable purchase of 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC) on June 24, 2026. This transaction occurred as the stock traded near $4.26 on Saturday.

Insider Buying and Selling at C4 Therapeutics, Inc.

Several insiders, including Utpal Koppikar, each bought 62,000 shares of C4 Therapeutics on June 24, 2026. These transactions were not part of any pre-planned trading program.

Other Institutional Activity in C4 Therapeutics

Morgan Stanley increased its holdings in C4 Therapeutics by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. Meanwhile, RA Capital Management, L.P. and Bain Capital Life Sciences Investors, LLC maintained their stakes at 8 million and 7,171,910 shares, respectively. Lynx1 Capital Management LP reduced its position by 99,231 shares to 6,998,902 shares, worth about $18.41 million. Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at $10.16 million.

C4 Therapeutics, Inc. Stock Up 10.6%

Shares of C4 Therapeutics, Inc. traded around $4.26 on Saturday. The company, with a market cap of about $471 million, has a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 2.93, indicating higher volatility compared to the market. It has a 52-week low of $1.40 and a high of $4.60, with a 50-day moving average of $3.51 and a 200-day moving average of $2.70.

Analysts Set New Price Targets

On June 1, 2026, Evercore ISI Group maintained its buy rating on C4 Therapeutics, setting a price target of $12. Barclays has consistently maintained a buy rating with various targets, including $7 and $10 in recent months. The consensus among analysts is a strong buy, with a mean target price of $13.33.

About C4 Therapeutics

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing new treatments to degrade proteins that cause diseases. The company's lead product, Cemsidomide, targets specific proteins in multiple myeloma and is in clinical trials. C4 Therapeutics also works on cancer treatments and has partnerships with major firms like Roche and Merck.

Bottom Line

Insider purchases at C4 Therapeutics reflect confidence in the company's future growth potential. Investors often watch such transactions for insights into management's view of the company's prospects. As a clinical-stage biotech firm, C4 Therapeutics remains a volatile investment, with its stock price subject to changes in clinical trial results and market conditions.